Newly confirmed benefit cuts by Cigna and PepsiCo are removing GLP-1 weight-loss coverage from U.S. employees even as Gallup data show adult use for weight loss tripling to 11% and Medicare begins offering the drugs for obesity at $50 per month. Bank of America reportedly spends $250 million a year…
Cigna has stopped covering GLP-1 weight-loss drugs through its own employee health plan, effective July 1. PepsiCo has scaled back GLP-1 coverage for its employees because of rising costs, while continuing to cover the drugs for employees who use them to manage diabetes. The cutbacks arrive as use of the drugs accelerates. A Gallup News poll from the month before publication found that 11% of U.S. adults currently take a GLP-1 medication specifically for weight loss, up from 3% in 2024.
The financial stakes explain the timing. Depending on insurance coverage, the specific drug, and manufacturers' cash-pay programs, out-of-pocket costs for GLP-1s range from $25 per month to more than $1,000 per month. For patients without coverage, the potential out-of-pocket cost is more than $1,000 per month. Cigna confirmed the July 1 change to its own employee health plan. A PepsiCo letter to affected employees described prescription weight loss medications as one of the fastest-growing costs in the PepsiCo Plans.
The private-sector retreat is unfolding just as the public sector moves the other way. Medicare began allowing eligible beneficiaries to receive GLP-1s for obesity by prescription at $50 per month, starting the month before publication. Employers are now making coverage decisions in a divided policy environment: a federal program with a flat $50 monthly patient cost, and an employer market where actual spending has outpaced projections. That divergence sets up a live test of how price shapes access to a drug class with demonstrated cardiovascular effects.
KFF research found that many employers see GLP-1 use running higher than expected and that covering the drugs significantly increased prescription drug costs, prompting consideration of scaling back coverage. Cigna's change applies to its own employee health plan; the year of the July 1 effective date is not specified. PepsiCo's cut is deliberately partial: the company continues to cover the drugs for employees who use them to manage diabetes, while the letter it sent to affected employees identified prescription weight loss medications as a leading cost driver in the PepsiCo Plans.
The dollar figures moving through large employer formularies are big enough to move budgets. Bank of America reportedly spends $250 million per year on GLP-1 drugs for its employees. That figure is reported, not independently confirmed, but it signals the order of magnitude that full coverage represents on a national scale. Eli Lilly's stated price for Zepbound ranges from $499 to $1,086.37 per fill, with the patient's payment depending on prescription drug insurance plan.
The United States Chamber of Commerce says 99.9% of U.S. businesses are small businesses, which can make GLP-1 coverage a health plan decision rather than an employer decision. For most of the employer market, the entity choosing the formulary is not a corporate benefits officer but an insurer or pharmacy benefit manager applying standard coverage rules. That diffuse decision structure complicates demand forecasting for manufacturers and creates uncertainty for clinicians who cannot tell, at the time of prescribing, whether a patient's plan will still cover the drug at the next fill.
Dr. Xiaoning Huang, assistant professor in the division of cardiology at Northwestern University Feinberg School of Medicine, said the spending shock is concentrated in a short window. "It's a sudden increase in healthcare expenditure for employers."
The Food and Drug Administration approvals that built this market came in three steps. The FDA approved the first GLP-1 medication in 2014, after which weight-loss use increased. The FDA approved Wegovy in 2021 and Zepbound in 2023, both for weight loss. Some GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists are approved for Type 2 diabetes, including Ozempic, Mounjaro, and Trulicity. Others are approved for weight loss, including Wegovy, Zepbound, and Saxenda.
That regulatory split has direct benefit consequences. Because the indications are distinct, an employer can restrict the weight-loss drugs while keeping the diabetes drugs covered, which is exactly what PepsiCo did. The dual GLP-1/GIP receptor agonists in the U.S. approvals, Mounjaro and Zepbound, add GIP receptor activity to GLP-1 receptor agonism, yet they sit on opposite sides of the coverage line: Mounjaro is approved for Type 2 diabetes, while Zepbound is approved for weight loss. A patient who loses weight-loss coverage but retains diabetes coverage therefore faces a formulary mismatch that no pharmacological distinction supports.
Medicare's new obesity benefit sits inside the same regulatory structure. Eligible beneficiaries can receive GLP-1s for obesity by prescription at $50 per month, with the coverage beginning the month before publication. The program does not change the FDA's indication boundaries, but it changes the comparison point for employers: if the federal government can deliver the drugs at a $50 monthly patient cost, the argument that commercial plans must drop them entirely becomes harder to sustain. Paul Fronstin, director of health benefits research at the nonprofit Employee Benefit Research Institute, said the employer calculation is broader than the price tag. "It's a business decision on multiple levels. It is not just about: Do we pay for this benefit or not, and how much does it cost us?"
GLP-1 is a peptide hormone released by the gut when a person eats. It helps the body produce more insulin, lower blood sugar, and slow digestion, which can help with weight loss. The drugs in this class are peptide-based therapies: GLP-1 receptor agonists mimic the endogenous hormone, and the dual agonists add activity at GIP, the other major incretin hormone, broadening the metabolic signal beyond what GLP-1 alone achieves.
The cardiovascular evidence is what makes the coverage question a medical one rather than a purely financial one. GLP-1s and dual GIP/GLP-1 medications decrease cardiovascular risk by lowering blood pressure, reducing systemic inflammation, and improving blood lipid profiles alongside weight loss. These effects matter most for the populations with the highest burden of obesity and Type 2 diabetes, and they are the reason cardiologists have become some of the most visible advocates for broad coverage.
Dr. Sadiya Khan, Magerstadt Professor of cardiovascular epidemiology at Northwestern University Feinberg School of Medicine, framed the tension directly. "we know that these medications are very effective at reducing cardiovascular disease risk, but they're not very affordable right now." Khan said research is still being done on the effects of patients stopping GLP-1s after losing coverage. The gap matters because the trials that established the cardiovascular benefits followed patients on continuous treatment. Discontinuation driven by a benefits change is a different exposure, with its own risks, and it remains uncharacterized.
Employer coverage decisions directly shape real-world access to peptide-based GLP-1 and dual GLP-1/GIP therapies, and the Cigna and PepsiCo changes mean a prescription written in June may not be covered in July. For clinicians, the practical task is contingency planning: confirm the patient's formulary status at the time of prescribing, identify the cash-pay price, and determine whether a manufacturer program can close the gap. For patients, the stakes are adherence and the cardiovascular protection the drugs provide.
Fronstin said the benefit decision is inseparable from the labor market. "What do we need to do to recruit and retain workers so that we can have a successful business? Health benefits are part of that equation." He also said employers may reconsider covering GLP-1s if prices fall, but people may already be used to paying for the drugs themselves. That observation points to a possible shift in how the market clears: if employer coverage contracts, patient demand does not disappear; it migrates to cash-pay channels and manufacturer discount programs.
For the research community, the coverage contraction sets a visible agenda. The questions include the health effects of discontinuation, the value of the drugs relative to their price, and the design of coverage policies that preserve cardiovascular benefit without breaking employer budgets. Health-services researchers now have a live comparison: a Medicare program offering GLP-1s for obesity at $50 per month running alongside employer plans that are dropping the same drugs for the same indication. Tracking outcomes across those populations could answer questions that the FDA approval trials and employer claims data cannot answer on their own.
The evidence behind the coverage story has real gaps. The Cigna change is dated July 1 but the year is not specified. The Gallup poll and the start of Medicare coverage are dated only as the month before publication. The Bank of America spending figure is reported, not independently confirmed. The identity of the first GLP-1 medication approved by the FDA in 2014 is not named. The out-of-pocket cost estimates are broad and depend on insurance coverage, the specific drug, and manufacturer cash-pay programs. Gallup poll and KFF research details, including sample sizes and methodology, are not available.
The open questions the coverage decisions leave unresolved:
The Cigna and PepsiCo decisions, and the Medicare expansion beside them, mark a transition in the short history of incretin-based peptide therapies. The FDA approvals established efficacy. The employer market established cost. The next phase of evidence will have to establish something neither group has yet produced: what happens to patients when a drug that works is taken away.
Peptides referenced: Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, GLP-1.
Related reading: Combination therapy, not stronger GLP-1s, will define obesity care, Updated review ranks tirzepatide top among GLP-1 weight-loss agents, Energean shares slide 12.3% in 2026 while Brent holds above $92, Seoul seizes 4,155 illegal Wegovy and Mounjaro imports in six months.